Pancreatic Cancer Research

ResearcherSanford ResearchActive in the last 2 years

Meena Jaggi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5034011054. Sources: OpenAlex.

Their work

Papers
23 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: none · 2017: 3 papers · 2018: 2 papers · 2019: 5 papers · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 23

  1. CEACAM7 expression contributes to early events of pancreatic cancer. Co-author DOI 10.1016/j.jare.2023.02.013↗
  2. Integrative big transcriptomics data analysis implicates crucial role of MUC13 in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2023.04.029↗
  3. Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. Co-author DOI 10.1038/s42003-022-04102-4↗
  4. Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. Last author DOI 10.3390/biomedicines9121814↗
  5. Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis in Pancreatic Cancer Cells and Enhances Gemcitabine Efficacy. Co-author DOI 10.1021/acsomega.0c00793↗
  6. Pluronic Polymer-Based Ormeloxifene Nanoformulations Induce Superior Anticancer Effects in Pancreatic Cancer Cells. Co-author DOI 10.1021/acsomega.9b03382↗
  7. Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. Last author DOI 10.1038/s41416-019-0629-9↗
  8. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2019.04.005↗
  9. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Co-author DOI 10.1016/j.nano.2019.102027↗
  10. Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. Co-author DOI 10.1186/s13046-018-1009-7↗
  11. Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer). Co-author DOI 10.3390/cells9010103↗
  12. Gemcitabine Combination Nano Therapies for Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics11110574↗
  13. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.12.003↗
  14. MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. Last author DOI 10.1038/s41389-018-0031-0↗
  15. Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. Co-author DOI 10.1007/s11605-016-3222-z↗
  16. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. Last author DOI 10.1038/onc.2016.218↗
  17. miR-145: Revival of a Dragon in Pancreatic Cancer. Co-author PMID 28616589↗
  18. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2015.02.082↗
  19. Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-2397↗
  20. Revisiting stroma in pancreatic cancer. First author DOI 10.18632/oncoscience.198↗
  21. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Co-author DOI 10.18632/oncotarget.2281↗
  22. Targeting microRNAs in pancreatic cancer: microplayers in the big game. Co-author DOI 10.1158/0008-5472.can-13-1288↗
  23. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Co-author DOI 10.1158/1535-7163.mct-12-1227↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Subhash C. Chauhan · 23 shared papers, 2013–2024 · strength 2.16
  2. Murali Mohan Yallapu · 21 shared papers, 2013–2024 · strength 2.03
  3. Sheema Khan · 19 shared papers, 2013–2024 · strength 1.70
  4. Sonam Kumari · 10 shared papers, 2017–2022 · strength 0.98
  5. Saini Setua · 8 shared papers, 2017–2020 · strength 0.71
  6. Bilal Bin Hafeez · 7 shared papers, 2017–2022 · strength 0.69
  7. Stephen W. Behrman · 9 shared papers, 2014–2022 · strength 0.65
  8. Mohammed Sikander · 7 shared papers, 2014–2022 · strength 0.60
  9. Neeraj Chauhan · 8 shared papers, 2013–2020 · strength 0.55
  10. Swati Dhasmana · 2 shared papers, 2023–2024 · strength 0.41
  11. Shafiul Haque · 2 shared papers, 2023–2024 · strength 0.41
  12. Anupam Dhasmana · 2 shared papers, 2023–2024 · strength 0.41
  13. Vivek Kumar Kashyap · 4 shared papers, 2018–2022 · strength 0.38
  14. Advait B. Shetty · 2 shared papers, 2019–2020 · strength 0.21
  15. Andrew E. Massey · 2 shared papers, 2019 · strength 0.17
  16. Zachary E. Stiles · 2 shared papers, 2018–2019 · strength 0.15
  17. Fathi T. Halaweish · 2 shared papers, 2015–2019 · strength 0.13
  18. Mehdi Chaib · 1 shared paper, 2022 · strength 0.13
  19. Kamalika Samanta · 1 shared paper, 2019 · strength 0.11
  20. Subash C. Gupta · 1 shared paper, 2018 · strength 0.09
  21. Wěi Li · 1 shared paper, 2019 · strength 0.08
  22. Deepak Kumar · 2 shared papers, 2013–2014 · strength 0.08
  23. Lei Wang · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.